NextCure (NXTC) Investor Presentation - Slideshow

ext Oure MAY 2023 Treating Cancer by Restoring Immune Function Forward-Looking Statements 2 DIFFERENTIATED PIPELINE Multiple clinical programs, novel targets and diverse indications CAPITAL EFFICIENCY $145.5M balance sheet, runway into mid-2025 QUALITY PRODUCT DEVELOPMENT Fully integrated operations drive innovation, internal manufacturing and capital efficiency the extent that statements contained in this presentation are not descriptions of historical facts, they may be deemed to be forward-looking statem ...